Chemomab Therapeutics Ltd Stock Story
CMMB Stock | USD 0.66 0.02 2.94% |
About 55% of Chemomab Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Chemomab Therapeutics Ltd suggests that many traders are impartial. Chemomab Therapeutics' investor sentiment overview provides quick insight into current market opportunities from investing in Chemomab Therapeutics Ltd. The current market sentiment, together with Chemomab Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Chemomab Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Chemomab Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Chemomab daily returns and investor perception about the current price of Chemomab Therapeutics Ltd as well as its diversification or hedging effects on your existing portfolios.
Chemomab |
Requested story not found. it has been either deleted or moved. View all stories for Chemomab Therapeutics Ltd.
Chemomab Therapeutics Latest Timeline
Chemomab Therapeutics is listed for 0.66. The company has return on total asset (ROA) of (0.488) % which means that it has lost $0.488 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9102) %, meaning that it created substantial loss on money invested by shareholders. Chemomab Therapeutics' management efficiency ratios could be used to measure how well Chemomab Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -1.04. The current year's Return On Capital Employed is expected to grow to -1.39. At present, Chemomab Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.02, whereas Total Assets are forecasted to decline to about 21.8 M.Check out Chemomab Therapeutics Hype Analysis, Chemomab Therapeutics Correlation and Chemomab Therapeutics Performance. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Chemomab Stock analysis
When running Chemomab Therapeutics' price analysis, check to measure Chemomab Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemomab Therapeutics is operating at the current time. Most of Chemomab Therapeutics' value examination focuses on studying past and present price action to predict the probability of Chemomab Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chemomab Therapeutics' price. Additionally, you may evaluate how the addition of Chemomab Therapeutics to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Chemomab Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemomab Therapeutics. If investors know Chemomab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemomab Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.06) | Return On Assets (0.49) | Return On Equity (0.91) |
The market value of Chemomab Therapeutics is measured differently than its book value, which is the value of Chemomab that is recorded on the company's balance sheet. Investors also form their own opinion of Chemomab Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Chemomab Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemomab Therapeutics' market value can be influenced by many factors that don't directly affect Chemomab Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemomab Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemomab Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.